Global Oncology Drugs Market Research Report 2022-2027: Untapped Emerging Economies and Rising Drugs in Pipeline –

The “Oncology Drugs Market Research Report by Indication (Bladder Cancer, Breast Cancer, and Cervical Cancer), Drug Class Type, Distribution, Region (Americas, Asia-Pacific, and Europe, Middle East and Africa) – Global forecast to 2027 – Cumulative The “Impact of COVID-19” report has been added to from offer.

The global oncology drug market size was estimated to be USD 114.02 billion in 2021, USD 122.71 billion in 2022, and is projected to grow at a compound annual growth rate (CAGR) of 7.80% to reach 178, 95 billion USD by 2027.

In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year and the years from 2023 to 2027 as the forecast period.

Cumulative impact of COVID-19:

COVID-19 is an unparalleled global public health emergency that has affected almost every industry, and the long-term effects are expected to impact industry growth over the forecast period. Our ongoing research amplifies our research framework to ensure inclusion of the underlying issues of COVID-19 and potential pathways forward.

The report provides insights into COVID-19 considering shifts in consumer behavior and demand, shopping patterns, supply chain rerouting, current market force dynamics, and significant interventions governments. The updated study provides insights, analysis, estimates, and forecasts considering the impact of COVID-19 on the market.

Competitive Strategy Window:

The strategic competitive window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or match between its capabilities and opportunities for future growth prospects.

It describes the optimal or favorable fit for vendors to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to execute further business expansion and growth. during a forecast period.

Market share analysis:

The market share analysis offers the analysis of the vendors considering their contribution to the overall market. It gives the idea of ​​its revenue generation in the overall market compared to other providers in the space. It provides information on the performance of vendors in terms of revenue generation and customer base compared to others.

Knowing the market share gives an idea of ​​the size and competitiveness of suppliers for the reference year. It reveals the characteristics of the market in terms of accumulation, fragmentation, dominance and merger.

Competitive scenario:

The competitive scenario provides an analysis of the prospects of the different business growth strategies adopted by the vendors. The news covered in this section provides valuable insights at various stages while keeping abreast of business news and engaging stakeholders in the economic debate.

The competitive scenario represents press releases or company news categorized into merger and acquisition, agreement, collaboration and partnership, new product launch and improvement, investment and financing, and awards, recognition and expansion. All the news gathered helps the vendor to understand the gaps in the market and the strength and weakness of the competitors, thus providing insights to improve the product and service.

Enterprise Usability Profiles:

  • AbbVie Inc.

  • Pharma Capacity

  • Acadie Pharmaceuticals Inc.

  • Aegerion Pharmaceuticals Inc.

  • Amgen Inc.

  • ARIAD Pharmaceuticals, Inc.

  • Aslan Pharmaceuticals Ltd.,

  • Aspen Pharmacare Holdings Limited

  • Astellas Pharma Inc.

  • AstraZeneca PLC

  • Athens, Inc.

  • Bayer AG

  • Boehringer Ingelheim GmbH

  • Bristol-Myers Squibb Company

  • Celgene Corporation

  • Eli Lilly and company

  • F. Hoffmann-La Roche Ltd.

  • Gilead Sciences Inc.

  • GlaxoSmithKline PLC

  • Johnson & Johnson Services, Inc.

  • Merck & Co., Inc.

  • Novartis International SA

  • Pfizer Inc.

  • Takeda Pharmaceutical Company Limited

  • Teva Pharmaceutical Industries

Main topics covered:

1. Preface

2. Research methodology

3. Executive Summary

4. Market Overview

5. Market Overview

5.1. Market dynamics

5.1.1. Drivers Increase in the incidence of cancer worldwide Rise of the global geriatric population Increase in public health spending High development of the biosimilar in the field of oncology

5.1.2. Constraints Adverse effects associated with the use of cancer drugs

5.1.3. Opportunities Untapped Emerging Economies Increase in the number of drugs in development

5.1.4. Challenges High drug cost

5.2. Cumulative impact of COVID-19

5.3. Cumulative impact of the 2022 Russian-Ukrainian conflict

6. Oncology Drugs Market, By Indication

6.1. Introduction

6.2. Bladder cancer

6.3. Breast cancer

6.4. Cervical cancer

6.5. Colorectal cancer

6.6. Esophageal cancer

6.7. kidney cancer

6.8. Liver cancer

6.9. Lung cancer

6.10. Prostate cancer

6.11. Stomach cancer

7. Oncology Drugs Market, By Drug Class Type

7.1. Introduction

7.2. Chemotherapy

7.3. Hormone therapy

7.4. Immunotherapy

7.5. Targeted therapy

8. Oncology Drugs Market, By Distribution

8.1. Introduction

8.2. Hospitals Pharmacies

8.3. Online pharmacies

8.4. Retail pharmacies

9. Americas Oncology Drug Market

9.1. Introduction

9.2. Argentina

9.3. Brazil

9.4. Canada

9.5. Mexico

9.6. United States

10. Asia Pacific Oncology Drug Market

10.1. Introduction

10.2. Australia

10.3. China

10.4. India

10.5. Indonesia

10.6. Japan

10.7. Malaysia

10.8. Philippines

10.9. Singapore

10.10. South Korea

10.11. Taiwan

10.12. Thailand

11. Europe, Middle East and Africa Oncology Drugs Market

11.1. Introduction

11.2. France

11.3. Germany

11.4. Italy

11.5. Netherlands

11.6. Qatar

11.7. Russia

11.8. Saudi Arabia

11.9. South Africa

11.10. Spain

11.11. United Arab Emirates

11.12. UK

12. Competitive Landscape

12.1. FPNV positioning matrix

12.2. Market Ranking Analysis

12.3. Market share analysis, by key player

12.4. Competitive scenario

13. Enterprise Usability Profiles

For more information about this report visit Oncology+Drugs +Market+research+report+2022-2027 %3a+Emerging+untapped+economies+%26+Rising+in+pipeline+drugs+count&utm_exec=chdo54prd

Comments are closed.